Stem cells in study against type 1 diabetes in children
“The results of this cell therapy are very promising and it has now been shown to be effective in type 1 diabetes in a randomized, placebo-controlled study in adults. We hope to see the same positive effect in children”, says Per-Ola Carlsson, Chief Physician and Professor at Uppsala University Hospital / Uppsala University
Allogeneic cell therapy has once again shown efficacy in type 1 diabetes
“Our vision is to improve treatment options for thousands, maybe millions of patients and reducing healthcare costs with the aid of stem cell therapy.” Mathias Svahn, CEO of Cellaviva and NextCell Pharma.
ProTrans shows significant effect in Diabetes
Cellaviva's parent company NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved...
Type 1 diabetes treatment with umbilical cord stem cells
NextCell expects ProTrans to be an effective treatment for autoimmune diseases NextCell expects ProTrans to be an effective treatment for autoimmune diseases, other inflammatory conditions and in transplant reactions following...
Crown Princess Victoria awards research prize to Cellaviva's Principal investigator
Cellaviva and NextCell Pharma's Principal investigator receive the award as Child Diabetes Researcher of the Year by Swedish Crown Princess Victoria. Cellaviva's Principal investigator for both our clinical studies with...
Covid-19 study shows the positive effect of treatment with stem cells
First studies testing the effect of mesenchymal stem cells in the treatment of COVID-19 have been published. In this contex, Dr. Leng and colleagues found that a single injection had an effect on 7 patients with COVID-19.
Can stem cells treat type 1 diabetes? Are stem cell transplants performed today? We keep you updated on news, as well as the latest developments in stem cell research. Our goal is for everyone in Sweden to be informed about the possibility of saving stem cells from the umbilical cord at birth. Our articles therefore focus on how this can be a unique investment for the future.
Focusing on stem cell research
Nextcell Pharma, a part of Cellaviva, researches daily to develop new cell therapies. We therefore share our own articles, news and articles on research from the rest of the world on stem cell treatment.
